AGP Executive Report
Last update: 8 hours agoFederal Oversight: The DEA denied Colorado cannabis company MedPharm Research a federal manufacturing license, citing conduct it said failed to meet federal standards. The decision underscores that state approval alone may not satisfy federal requirements. Surgical Safety: A review of five studies covering 44,312 patients linked cannabis use to a 46% higher risk of heart attack during or shortly after surgery. Researchers also found a lower risk of blood clots; the findings show an association, not proof of cause. Patients should tell their anesthesiologist about cannabis use. Hemp Rules: Hemp-derived THC businesses face mounting uncertainty as proposed federal restrictions and tightening state rules threaten products and sales. Ballot Stakes: Massachusetts voters will decide Nov. 3 whether to repeal recreational cannabis sales, as lawmakers urge them to keep the market legal.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
